vs
CXApp Inc.（CXAI）与Prime Medicine, Inc.（PRME）财务数据对比。点击上方公司名可切换其他公司
CXApp Inc.的季度营收约是Prime Medicine, Inc.的1.2倍（$1.0M vs $838.0K），CXApp Inc.净利率更高（-544.1% vs -5498.7%，领先4954.6%），CXApp Inc.同比增速更快（-38.5% vs -61.6%），CXApp Inc.自由现金流更多（$-3.6M vs $-37.5M）
CXApp Inc.是一家专注于数字工作场所体验解决方案的科技企业，提供员工参与度提升、办公空间优化、访客管理、混合办公协调等云服务产品，主要服务北美、亚太、欧洲的中大型企业客户。
Prime Medicine, Inc.是一家总部位于美国马萨诸塞州剑桥的生物科技企业，核心业务是依托先导编辑技术开发新型基因治疗方案，致力于为遗传病等相关疾病探索创新治疗手段，推动前沿基因编辑技术的临床转化与应用。
CXAI vs PRME — 直观对比
营收规模更大
CXAI
是对方的1.2倍
$838.0K
营收增速更快
CXAI
高出23.1%
-61.6%
净利率更高
CXAI
高出4954.6%
-5498.7%
自由现金流更多
CXAI
多$33.9M
$-37.5M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0M | $838.0K |
| 净利润 | $-5.6M | $-46.1M |
| 毛利率 | 86.9% | — |
| 营业利润率 | -576.9% | -5800.5% |
| 净利率 | -544.1% | -5498.7% |
| 营收同比 | -38.5% | -61.6% |
| 净利润同比 | -56.7% | -9.0% |
| 每股收益（稀释后） | — | $-0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CXAIPRME
| Q4 25 | $1.0M | $838.0K | ||
| Q3 25 | $1.1M | $1.2M | ||
| Q2 25 | $1.2M | $1.1M | ||
| Q1 25 | $1.2M | $1.5M | ||
| Q4 24 | $1.7M | $2.2M | ||
| Q3 24 | $1.9M | — | ||
| Q2 24 | $1.8M | $0 | ||
| Q1 24 | $1.8M | $591.0K |
净利润CXAIPRME
| Q4 25 | $-5.6M | $-46.1M | ||
| Q3 25 | $-3.2M | $-50.6M | ||
| Q2 25 | $-3.1M | $-52.6M | ||
| Q1 25 | $-1.6M | $-51.9M | ||
| Q4 24 | $-3.5M | $-42.3M | ||
| Q3 24 | $-5.4M | — | ||
| Q2 24 | $-5.3M | $-55.3M | ||
| Q1 24 | $-5.2M | $-45.8M |
毛利率CXAIPRME
| Q4 25 | 86.9% | — | ||
| Q3 25 | 89.0% | — | ||
| Q2 25 | 86.0% | — | ||
| Q1 25 | 87.7% | — | ||
| Q4 24 | 86.0% | — | ||
| Q3 24 | 80.4% | — | ||
| Q2 24 | 80.0% | — | ||
| Q1 24 | 82.0% | — |
营业利润率CXAIPRME
| Q4 25 | -576.9% | -5800.5% | ||
| Q3 25 | -343.4% | -4406.0% | ||
| Q2 25 | -336.1% | -4787.2% | ||
| Q1 25 | -306.0% | -3603.3% | ||
| Q4 24 | -169.7% | -2025.7% | ||
| Q3 24 | -194.3% | — | ||
| Q2 24 | -206.7% | — | ||
| Q1 24 | -197.3% | -8179.5% |
净利率CXAIPRME
| Q4 25 | -544.1% | -5498.7% | ||
| Q3 25 | -283.4% | -4129.1% | ||
| Q2 25 | -256.7% | -4716.7% | ||
| Q1 25 | -132.0% | -3568.8% | ||
| Q4 24 | -213.6% | -1936.6% | ||
| Q3 24 | -286.5% | — | ||
| Q2 24 | -297.6% | — | ||
| Q1 24 | -284.4% | -7743.0% |
每股收益（稀释后）CXAIPRME
| Q4 25 | — | $-0.22 | ||
| Q3 25 | — | $-0.32 | ||
| Q2 25 | — | $-0.41 | ||
| Q1 25 | — | $-0.40 | ||
| Q4 24 | — | $-0.31 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-0.46 | ||
| Q1 24 | — | $-0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $11.1M | $63.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $14.0M | $120.9M |
| 总资产 | $32.4M | $342.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CXAIPRME
| Q4 25 | $11.1M | $63.0M | ||
| Q3 25 | $5.1M | $71.4M | ||
| Q2 25 | $4.9M | $53.8M | ||
| Q1 25 | $3.9M | $91.9M | ||
| Q4 24 | $4.9M | $182.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $55.6M | ||
| Q1 24 | — | $94.2M |
股东权益CXAIPRME
| Q4 25 | $14.0M | $120.9M | ||
| Q3 25 | $15.2M | $161.8M | ||
| Q2 25 | $14.3M | $60.9M | ||
| Q1 25 | $15.6M | $106.9M | ||
| Q4 24 | $15.6M | $153.1M | ||
| Q3 24 | $13.6M | — | ||
| Q2 24 | $16.3M | $196.6M | ||
| Q1 24 | $20.9M | $243.8M |
总资产CXAIPRME
| Q4 25 | $32.4M | $342.7M | ||
| Q3 25 | $28.5M | $385.0M | ||
| Q2 25 | $29.6M | $279.0M | ||
| Q1 25 | $29.3M | $328.2M | ||
| Q4 24 | $31.8M | $297.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $259.7M | ||
| Q1 24 | — | $311.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.6M | $-37.3M |
| 自由现金流经营现金流 - 资本支出 | $-3.6M | $-37.5M |
| 自由现金流率自由现金流/营收 | -355.5% | -4480.4% |
| 资本支出强度资本支出/营收 | 0.2% | 34.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-10.4M | $-167.1M |
8季度趋势，按日历期对齐
经营现金流CXAIPRME
| Q4 25 | $-3.6M | $-37.3M | ||
| Q3 25 | $-2.8M | $-35.0M | ||
| Q2 25 | $-3.0M | $-41.4M | ||
| Q1 25 | $-979.0K | $-48.9M | ||
| Q4 24 | $-2.7M | $16.2M | ||
| Q3 24 | $-2.1M | — | ||
| Q2 24 | $-1.9M | $-45.5M | ||
| Q1 24 | $-650.0K | $-67.7M |
自由现金流CXAIPRME
| Q4 25 | $-3.6M | $-37.5M | ||
| Q3 25 | $-2.8M | $-35.3M | ||
| Q2 25 | $-3.0M | $-43.0M | ||
| Q1 25 | $-984.0K | $-51.3M | ||
| Q4 24 | — | $14.5M | ||
| Q3 24 | $-2.1M | — | ||
| Q2 24 | $-1.9M | $-47.4M | ||
| Q1 24 | $-668.0K | $-70.0M |
自由现金流率CXAIPRME
| Q4 25 | -355.5% | -4480.4% | ||
| Q3 25 | -248.1% | -2880.5% | ||
| Q2 25 | -247.2% | -3855.1% | ||
| Q1 25 | -80.4% | -3526.8% | ||
| Q4 24 | — | 662.1% | ||
| Q3 24 | -109.3% | — | ||
| Q2 24 | -108.6% | — | ||
| Q1 24 | -36.7% | -11849.6% |
资本支出强度CXAIPRME
| Q4 25 | 0.2% | 34.6% | ||
| Q3 25 | 0.4% | 20.2% | ||
| Q2 25 | 0.9% | 141.0% | ||
| Q1 25 | 0.4% | 166.6% | ||
| Q4 24 | 0.0% | 82.0% | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 0.5% | — | ||
| Q1 24 | 1.0% | 393.2% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
